Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-ASP: Stopping vs Continuing Aspirin in Noncardiac Surgery
NCT03184805Terminated
- Sponsor
- Yonsei University
- Start
- Jun 2017
- Primary completion
- Apr 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of aspirin in coronary artery disease (CAD) (2 arms), sponsored by Yonsei University. Primary endpoint: Composite of cardiac death, nonfatal myocardial infarction (MI), cerebrovascular accident, definite or probable stent thrombosis, any revascularization and BARC ≥3 bleeding. Started Jun 2017; status: terminated.
02
Drugs
aspirin
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03184805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03184805.